The leading advisor for the UK science and technology (S&T) sectors has estimated that despite Brexit, Cambridge and Oxford’s S&T companies will require 2.5 million more square feet of lab and research space over the next five years, and are looking to accommodate 20,000 new R&D workers by 2023.
Esketamine, a Johnson & Johnson antidepressant based on the party drug ketamine, has received backing from an FDA independent advisory group.
Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.
Genomics England, NHS England and The Royal Society are holding a scientific meeting at the Royal Society in Carlton House Terrace to celebrate the successful conclusion of the 100,000 Genomes Project, which was declared finished in December last year.
More errors occur in DNA replication during times of stress when resources are scares, scientists at the University of Toronto have found.
For the first time, scientists have changed human stem cells into functional insulin-producing cells in mice, potentially promising a breakthrough in treatment for those suffering from type 1 diabetes.
Oxford Nanopore has launched its two new “109” cDNA kits, which provide high throughput while generating complete sequences of full-length cDNA strands with a low input option of just 1ng PolyA+ RNA.
Genomics industry professionals working in the USA are the highest paid in the world and their UK colleagues earn on average less than half as much. This was one of the most striking findings from the second annual Genomics Industry Workforce survey report published this week by Front Line Genomics and Paramount Recruitment.
Scientists at the Institute of Neuroscience (ION) in China have reportedly used gene-editing technology to disable a certain gene vital to sleep-cycle in macaque monkeys. This prototype could create populations of genetically identical monkeys to allow scientists to better study the mechanisms of complex human disorders.
The introduction of multi-omic research, the advancement of AI and machine learning to improve nearly every aspect of sequencing and data analysis, are just some of the big changes that will only become more prevalent in the future. We spoke to Angela Douglas MBE, Scientific Director of Genetics Laboratories at Liverpool Women’s Hospital, for her opinions on the changing nature of genomics and the trends to watch out for.
The Personal Genetics Education Project (pgEd) is an organisation which firmly believes in expanding genetics knowledge even further afield and increase awareness of the benefits and societal implications of personal genetics. We spoke to them about their goals, their concerns, and some of their biggest successes to date.
Genomics England has announced the appointment of Jonathan Symonds CBE as its new Chair to replace Sir John Chisholm, who leaves the organisation on 29 January 2019. Genomics England’s CEO, Professor John Mattick, is also stepping down to be temporarily replaced by Genomic England’s current Chief Scientist, Professor Mark Caulfield.
With so many talks and panels occurring across our four stages and Live Lounge, we understand that it can be pretty hard to pick out the most unmissable discussions at the festival this year. Given the conundrum, we thought we’d help out! We’ve selected a couple of talks and panels occurring across the two days which we think will be incredibly interesting and enormously informative for a whole range of people.
Front Line Genomics was created with a social mission after our founder lost his father to mesothelioma, a rare form of cancer commonly caused by exposure to asbestos. That’s why we thought it so important to showcase Nick Sireau, who co-founded the AKU Society to combat the disease, and is now about to finish a seven-year study into a drug which play a major part in eradicating AKU altogether.